Table 2 Baseline characteristics in two study groups
Category | Intervention group (N = 16) | Control group (N = 19) | |
|---|---|---|---|
Gender | Female | 15 (93.8%) | 17 (89.5%) |
Male | 1 (6.2%) | 2 (10.5%) | |
Age (years)- Mean (standard deviation) | 37.1 (9.7) | 37.3 (9.2) | |
Migraine duration (years)- Mean (standard deviation) | 16.2 (10.9) | 9.3 (8.1) | |
Education | High school diploma | 7 (43.8%) | 8 (42.1%) |
Bachelor’s degree | 5 (31.3%) | 7 (36.8%) | |
Master’s degree | 3 (18.8%) | 3 (15.8%) | |
PhD or equivalent | 1 (6.3%) | 1 (5.3%) | |
Job | Unemployed/ Housewife | 10 (62.5%) | 8 (44.4%) |
Student | 1 (6.3%) | 2 (11.1%) | |
Teacher | 1 (6.3%) | 2 (11.1%) | |
University professor | 1 (6.3%) | 1 (5.6%) | |
Accountant | 1 (6.3%) | 0 | |
Manager | 1 (6.3%) | 0 | |
Self-employed | 0 | 2 (11.1%) | |
Other | 1 (6.3%) | 3 (16.7%) | |
Prefer not to say | 0 | 1 (5.6%) | |
Migraine medications | Sodium valproate, 200 mg or 400 mg daily | 13 (81.3%) | 18 (94.7%) |
Maprotiline, 20 mg daily | 7 (43.8%) | 5 (26.3%) | |
Verapamil, 20 mg daily | 4 (25%) | 7 (36.8%) | |
Propranolol, 20 or 40 mg daily | 4 (25%) | 10 (52.6%) | |
Sertraline, 50 mg daily | 2 (12.5%) | 4 (21.1%) | |
Nortriptyline, 20 mg daily | 1 (6.3%) | 0 | |
Topiramate, 200 mg daily | 1 (6.3%) | 0 | |
Doxepin, 10 mg daily | 1 (6.3%) | 0 | |
Metoprolol, 40 mg daily | 1 (6.3%) | 1 (5.3%) | |
Amitriptyline, 20 mg | 0 | 1 (5.3%) | |
Citalopram, 20 mg | 0 | 1 (5.3%) | |
Other diseases | Gastroesophageal reflux disease | 1 (6.3%) | 0 |
Hyperlipidemia | 1 (6.3%) | 1 (5.3%) | |
Hypothyroidism | 0 | 1 (5.3%) | |
Inflammatory bowel disease | 1 (6.3%) | 0 | |
Mild asthma | 0 | 1 (5.3%) | |
Multiple sclerosis | 1 (6.3%) | 0 | |
Mostly used pain relievers | Acetaminophen | 0 | 1 (5.3%) |
Diclofenac (supp) | 1 (6.3%) | 2 (10.5%) | |
Ibuprofen (tab) | 6 (37.5%) | 9 (47.4%) | |
Ibuprofen (cap) | 0 | 6 (31.6%) | |
Mixed pain relievers (acetaminophen, ibuprofen, caffeine) | 9 (56.3%) | 0 | |